Novo Nordisk continues Clayton, USA, expansion

11 May 2003

Novo Nordisk has awarded a contract to BE&K Engineering and SuittConstruction for a 19,000-square-foot expansion of its insulin manufacturing facility in Clayton, USA. The company plans to break ground on the $12 million new addition in June.

The Clayton manufacturing facility handles the formulation, filling and packaging of Novo Nordisk's genetically-engineered insulin preparations. The site is a high-volume, high-speed, integrated facility that supplies the needs of the US and other worldwide markets. The new two-story addition will expand the facility's quality inspection and cold storage capabilities and quality control laboratories. It also will provide additional administrative and employee areas, the company notes.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

A biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes.